Immuron Limited (IMC) AI Stock Analysis

• Market Cap: AU$14.97M
• Dividend Yield: N/A
• Average Volume (3M): 57.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: 82.90%
• EPS Growth: -89.41%
• Country: AU
• Employees: 7
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 233,959,010
• 10 Day Avg. Volume: 73,289
• 30 Day Avg. Volume: 57,627
• PEG Ratio: -0.09
• Price to Book (P/B): 2.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

Immuron Limited's overall stock score is driven primarily by financial performance and technical analysis. The rapid revenue growth is overshadowed by significant profitability and cash flow challenges, reflected in a moderately low financial performance score. The technical analysis suggests a bearish trend, and the valuation highlights the company's lack of profitability and absence of dividend yield, contributing to the overall low score.

Immuron Limited Business Overview & Revenue Model

Company Description

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

How the Company Makes Money

Immuron Limited generates revenue primarily through the sale of its lead product, Travelan, which is marketed as a dietary supplement for the prevention of travelers' diarrhea. The company also earns income from research and development collaborations, grants, and potential licensing agreements related to its proprietary technologies and product candidates. By targeting both consumer health markets and clinical applications, Immuron diversifies its revenue streams and enhances its potential for financial growth. Strategic partnerships with research institutions and pharmaceutical companies further contribute to its earnings by providing avenues for co-development and commercialization of new therapeutic products.

Immuron Limited Financial Statement Overview

Summary

Immuron Limited is experiencing rapid revenue growth with a 171% increase, but remains unprofitable with a significant negative net profit margin of -141.4%. The balance sheet is strong with a high equity ratio and low leverage, although cash flow challenges persist with negative operating and free cash flows.

Income Statement

Immuron Limited has shown substantial growth in revenue from $1.8M to $4.9M between 2023 and 2024, a revenue growth rate of approximately 171%. However, the company remains unprofitable, with a significant negative net profit margin of -141.4% in 2024. The persistent negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The company maintains a strong equity position with a high equity ratio of 81.7% as of 2024. The debt-to-equity ratio is low, indicating low leverage risk. However, a decrease in stockholders' equity from 2023 to 2024 suggests potential challenges in maintaining capital strength.

Cash Flow

Operating cash flow remains negative, highlighting cash flow management challenges. The free cash flow also deteriorated significantly in 2024, growing negatively by over 122%. There is a notable discrepancy between operating cash flow and net income, pointing to inefficient cash utilization.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	6.54M	4.90M	1.80M	765.19K	145.78K	2.52M
Gross Profit	4.41M	3.34M	1.31M	523.50K	94.70K	1.83M
EBITDA	-5.89M	-6.19M	-3.80M	-3.08M	-8.33M	-3.17M
Net Income	-7.35M	-6.94M	-3.79M	-2.85M	-8.38M	-2.93M
Balance Sheet
Total Assets	12.17M	15.55M	21.99M	24.86M	27.05M	6.20M
Cash, Cash Equivalents and Short-Term Investments	7.74M	11.66M	18.99M	22.11M	25.05M	3.25M
Total Debt	135.62K	173.50K	189.09K	209.79K	20.50K	61.10K
Total Liabilities	1.83M	2.84M	2.37M	1.68M	1.16M	558.25K
Stockholders Equity	10.34M	12.71M	19.62M	23.18M	25.90M	5.64M
Cash Flow
Free Cash Flow	-7.87M	-5.56M	-2.50M	-3.14M	-4.09M	-3.17M
Operating Cash Flow	-7.87M	-5.56M	-2.49M	-3.13M	-4.08M	-3.16M
Investing Cash Flow	228.05K	327.56K	-2.74M	-10.05K	-6.63K	-864.00
Financing Cash Flow	-17.90K	829.00	-35.02K	-36.26K	26.49M	1.17M

Immuron Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMC, the sentiment is Neutral. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.97 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:IMC.

Immuron Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NSB	54 Neutral	AU$43.23M	17.07	26.99%	―	―	51.85%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
IMC	51 Neutral	AU$14.97M	―	-52.70%	―	82.90%	-89.41%
1AD	46 Neutral	AU$2.68M	―	-392.18%	―	―	34.26%
AVE	46 Neutral	AU$11.11M	―	-64.72%	―	139.19%	33.33%
NOX	36 Underperform	AU$14.61M	―	-42.50%	―	―	80.96%
ANR	27 Underperform	AU$1.28M	―	-147.32%	―	―	26.09%

Immuron Limited Corporate Events

BNYMC Increases Stake in Immuron Limited

Immuron Limited has announced a change in the substantial holding of its shares by The Bank of New York Mellon Corporation (BNYMC) and its associated entities. The voting power of BNYMC Group in Immuron Limited has increased from 33.12% to 34.17%, indicating a slight increase in their influence over the company’s decisions. This change reflects BNYMC’s continued interest and investment in Immuron, potentially impacting the company’s strategic direction and stakeholder interests.

Immuron Limited Issues New Shares in Compliance with Corporations Act

Immuron Limited has issued 116,680 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, as per section 708A(5) of the Act. The company has complied with relevant provisions of the Corporations Act and confirms there is no excluded information required to be disclosed, indicating a transparent and compliant operation that may reassure stakeholders.

Immuron Limited Poised for Record Sales and Clinical Advancements

Immuron Limited is on track to surpass A$7 million in sales this financial year, marking a significant increase from the previous year’s A$4.9 million. The company is advancing several clinical trials, including Travelan® for traveler’s diarrhea, with results expected in October 2025, and plans to submit an IND for IMM-529 to the FDA in August 2025. Additionally, Immuron is preparing to launch ProIBS® in Australia, targeting the IBS treatment market. These developments could enhance Immuron’s market presence and strengthen its relationships with key stakeholders, including the US Department of Defense.

Immuron Limited Issues New Shares in Compliance with Corporations Act

Immuron Limited has issued 135,800 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company has complied with the relevant provisions of the Corporations Act and confirms there is no excluded information required to be disclosed, indicating a transparent and compliant operational stance.

Immuron Limited Announces Quotation of New Securities on ASX

Immuron Limited has announced the application for quotation of 135,800 fully paid ordinary securities on the Australian Securities Exchange (ASX), with an issue date of May 29, 2025. This move is part of previously announced transactions and may enhance the company’s market presence and liquidity, potentially impacting its operations and stakeholder interests positively.

Immuron Limited Announces Proposed Securities Issue

Immuron Limited has announced a proposed issue of 135,800 fully paid ordinary securities, with the issuance date set for May 29, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s market positioning by increasing its capital base and enhancing its financial flexibility.

Immuron Limited Announces New Share Issuance

Immuron Limited has issued 179,664 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant provisions. This issuance reflects the company’s ongoing adherence to regulatory requirements, potentially impacting its market operations and stakeholder interests.

Immuron Limited Announces Cessation of Performance Rights

Immuron Limited announced the cessation of 285,741 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation may impact the company’s capital structure and could have implications for stakeholders, reflecting challenges in meeting performance conditions.

Immuron Limited Announces New Securities Issuance

Immuron Limited has announced a new issuance of 179,664 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure and potentially improve its market position, signaling a proactive approach to leveraging financial instruments for growth.

Immuron Limited Achieves Record Sales with Travelan®

Immuron Limited has achieved its highest sales in history, exceeding AUD$5 million in a fiscal year, driven by strong performance in both Australia and North America. The company’s Travelan® product has seen significant growth, with year-to-date sales up 46% globally compared to the previous year. This growth is attributed to strategic marketing efforts, expanded pharmacy agreements in Australia, and successful relaunch efforts in Canada. The company anticipates continued strong sales momentum through upcoming holiday periods, further solidifying its market position.